Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has announced the launch of Pomalidomide Capsules in 1 mg, 2 mg, 3 mg, and 4 mg strengths in the United States market. This product is the generic equivalent of Pomalyst® Capsules from BMS Pharmaceuticals Corp. Eugia Pharma Specialities Limited was among the first to file an Abbreviated New Drug Application (ANDA) for this product. The manufacturing of Pomalidomide Capsules will take place at Eugia's Unit-I facility. The U.S. market for Pomalidomide Capsules has an estimated size of approximately US$ 3.3 billion for the twelve months ending January 2026, according to IQVIA MAT data. Pomalidomide is utilized as a third-generation immunomodulatory drug (IMiD) for treating relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma, often in combination with other medications.
